Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs ‘in’ rheumatoid arthritis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs ‘in’ rheumatoid arthritis
Authors
Keywords
-
Journal
International Journal of Clinical Pharmacy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-21
DOI
10.1007/s11096-020-01171-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-
- (2018) Kosuke Ebina et al. PLoS One
- Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan
- (2018) Masakazu Kondo et al. Modern Rheumatology
- Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers
- (2017) Maïté de La Forest Divonne et al. JOINT BONE SPINE
- The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study
- (2016) Yuan An et al. CLINICAL RHEUMATOLOGY
- Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry
- (2016) Ennio Giulio Favalli et al. ARTHRITIS CARE & RESEARCH
- Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.
- (2014) S. Saturni et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
- (2013) M Neovius et al. ANNALS OF THE RHEUMATIC DISEASES
- Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?
- (2013) Daniel H. Solomon et al. Arthritis & Rheumatology
- Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
- (2012) Ryoko Sakai et al. ANNALS OF THE RHEUMATIC DISEASES
- Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors
- (2012) F. IANNONE et al. JOURNAL OF RHEUMATOLOGY
- Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry
- (2011) J. A. MARKENSON et al. JOURNAL OF RHEUMATOLOGY
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
- (2009) Antonio Marchesoni et al. Annals of the New York Academy of Sciences
- Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
- (2009) Sophie Martin Du Pan et al. ARTHRITIS AND RHEUMATISM
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started